Fig. 5From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatmentThe overall survival in the higher and lower NLR groups who received a) abiraterone acetate or b) enzalutamideBack to article page